About
Small Molecules
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Team (11)
Anders Lundstrom
Non-Executive Director
Shield Therapeutics
team_member
Andy Hurley
Chief Commercial Officer
Shield Therapeutics
team_member
David Childs
VP of Manufacturing and Strategic Alliance
Shield Therapeutics
executive
Dr Christian Schweiger, MD, PhD
Non-Executive Director
Shield Therapeutics
team_member
Dr Jackie Mitchell
VP Quality, Clinical and Regulatory Affairs
Shield Therapeutics
executive
Dr Rudolf Widmann
Non Executive Director
Shield Therapeutics
team_member
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
8
As Collaborator
1
Total Enrollment
917
By Phase
PHASE3: 5PHASE1: 2
By Status
COMPLETED: 9
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT05126901Lead Sponsor
Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years
PHASE3Completed
65 participants
Started: Nov 3, 2021 · Completed: Jun 9, 2024
NCT04626414Lead Sponsor
Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers
PHASE1Completed
32 participants
Started: Sep 28, 2020 · Completed: Nov 13, 2020
NCT03382275Collaborator
EXPLorative Data Collection for Patient chAracterIzation, treatmeNt Pathways and Outcomes of IRON Preparations
N/ACompleted
51 participants
Started: Jan 16, 2018 · Completed: Apr 20, 2019
NCT03247816Lead Sponsor
Feraccru® Real World Effectiveness Study in Hospital Practice ( FRESH )
N/ACompleted
59 participants
Started: Aug 14, 2017 · Completed: Oct 1, 2018
NCT03181451Lead Sponsor
Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency
PHASE1Completed
37 participants
Started: Mar 14, 2017 · Completed: Mar 28, 2018
Locations (1)
Headquarters
Wellesley, MA, United States
Map
Loading map...